Ftse Mib
34.192,18
-0,30%
DAX
18.033,31
-0,54%
S&P 500
5.116,17
0,32%
NASDAQ Composite
15.983,08
0,35%
Bitcoin
62.045,42
-2,81%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adma Biologics Inc (ADMA) Adma Biologics Inc (ADMA) Notizie

Adma Biologics Inc

ADMA
6,58
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
11/3/202421:05EDGAR2Form 8-K - Current report
11/3/202417:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
11/3/202412:00GLOBEADMA Biologics Announces FDA Approvals of Extended Room..
09/3/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:05EDGAR2Form 8-K - Current report
05/3/202413:00GLOBEADMA Biologics to Participate in the Raymond James..
05/3/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:21EDGAR2Form 8-K - Current report
28/2/202422:15EDGAR2Form 8-K - Current report
28/2/202422:10GLOBEADMA Biologics Announces CFO Transition
28/2/202422:05GLOBEADMA Biologics Announces Fourth Quarter and Full Year 2023..
28/2/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202422:05GLOBEADMA Biologics to Report Fourth Quarter and Full Year 2023..
21/2/202414:00EDGAR2Form 8-K - Current report
21/2/202413:00GLOBEADMA Biologics Successfully Implements Innovative AI..
14/2/202417:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/1/202414:00EDGAR2Form 8-K - Current report
08/1/202413:30EDGAR2Form 8-K - Current report
08/1/202413:00GLOBEADMA Biologics Announces Preliminary Fourth Quarter 2023..
06/1/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202322:05GLOBEADMA Biologics Announces $135 Million Non-Dilutive..
12/12/202322:30EDGAR2Form 8-K - Current report
12/12/202313:00GLOBEADMA Biologics Announces FDA Approval for BIVIGAM® in the..
16/11/202322:31EDGAR2Form 8-K - Current report
16/11/202313:00GLOBEADMA BioCenters Receives FDA Approval for its Tenth Plasma..
08/11/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:36EDGAR2Form 8-K - Current report
08/11/202322:05GLOBEADMA Biologics Announces Third Quarter 2023 Financial..
01/11/202312:00GLOBEADMA Biologics to Report Third Quarter 2023 Financial..
04/10/202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202322:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202322:45EDGAR2Form 8-K - Current report
30/8/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202301:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202323:09EDGAR2Form 144 - Report of proposed sale of securities
19/8/202303:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202318:58EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
18/8/202303:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202302:47EDGAR2Form 144 - Report of proposed sale of securities
09/8/202323:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202322:15EDGAR2Form 8-K - Current report
09/8/202322:05GLOBEADMA Biologics Announces Second Quarter 2023 Financial..
02/8/202313:00GLOBEADMA Biologics to Report Second Quarter 2023 Financial..
19/7/202313:30EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 6,58

La tua Cronologia

NASDAQ
ADMA
Adma Biologics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network